Turisteron | CAS#28913-23-7

MedKoo Cat#: 462663 | Name: Turisteron

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Turisteron is an estrogen medication which has been used in birth control pills for women and in the treatment of prostate cancer in men. It has also been investigated in the treatment of breast cancer in women.

Chemical Structure

Turisteron

CAS#28913-23-7

Theoretical Analysis

MedKoo Cat#: 462663

Name: Turisteron

CAS#: 28913-23-7

Chemical Formula: C23H30O4S

Exact Mass: 402.1865

Molecular Weight: 402.55

Elemental Analysis: C, 68.63; H, 7.51; O, 15.90; S, 7.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Turisteron; Ethinyl estradiol isopropylsulfonate;

IUPAC/Chemical Name

(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl propane-2-sulfonate

InChi Key

KPEUDULLQDHKAZ-VROINQGHSA-N

InChi Code

InChI=1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1

SMILES Code

CC(S(=O)(Oc1cc2c([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@]4(C#C)O)C)cc1)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 402.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Böhm WD, Gorski J, Geissler W, Illig HD, Koch R. Zum klinischen Wert von Athinylöstradiolsulfonat (Turisteron)--Langzeitergebnisse einer randomisierten Verbundstudie [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long- term results of a randomized compound study]. Z Urol Nephrol. 1987 Mar;80(3):159-64. German. PMID: 2440199. 2: Stahl F, Schnorr D, Bär CM, Fröhlich G, Dörner G. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer. Exp Clin Endocrinol. 1989;94(3):239-43. doi: 10.1055/s-0029-1210905. PMID: 2630306. 3: Dörner G, Schnorr D, Stahl F, Rohde W. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron). Exp Clin Endocrinol. 1985 Dec;86(2):190-6. doi: 10.1055/s-0029-1210486. PMID: 3912197. 4: Gürtler R, Tanneberger S, Bodek B, Morack G. Turisteron: Klinische Erfahrungen mit einem Depot-Ostrogen bei der Behandlung des metastasierenden Mammakarzinoms [Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)]. Arch Geschwulstforsch. 1982;52(2):129-39. German. PMID: 7103689. 5: Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R. Die zellvermittelte Immunität (CMI) beim Prostatakarzinom unter Einfluss von Cytonal, Estrazyt und Turisteron [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron]. Z Urol Nephrol. 1987 Mar;80(3):139-47. German. PMID: 3300097. 6: Drawz B, Hoffmann L, Drawz G, Russbüldt R. Erfahrungen bei der Behandlung des fortgeschrittenen Prostatakarzinoms mit Turisteron unter besonderer Berücksichtigung kardiovaskulärer Komplikationen [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications]. Z Urol Nephrol. 1987 Mar;80(3):171-5. German. PMID: 3604473. 7: Stahl F, Schnorr D, Rohde W, Dörner G. Auffallend starke Hemmung des freien, biologisch aktiven Testosteronspiegels durch Behandlung mit Turisteron bei Patienten mit Prostatakarzinom [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):135-8. German. PMID: 3604472. 8: Guddat HM, Schnorr D, Zemke F. Erste Ergebnisse der multizentrischen klinischen Prüfung Stufe IV von Turisteron zur Therapie des Prostatakarzinoms [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):165-70. German. PMID: 3300098. 9: Guddat HM, Schnorr D, Dörner G, Stahl F, Rohde W. Das Verhalten der Serumspiegel von LH, FSH, Gesamttestosteron (GT), freiem Testosteron (FT) und SHBG unter der Therapie des Prostatakarzinoms mit Turisteron (Ethinylestradiolsulfonat) [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)]. Z Urol Nephrol. 1987 Dec;80(12):665-8. German. PMID: 3126615. 10: Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM. Zur konservativen Therapie des Prostatakarzinoms mit Turisteron [Conservative therapy of prostate cancer using Turisteron]. Z Urol Nephrol. 1987 Mar;80(3):149-57. German. PMID: 3111122. 11: Sladczyk E. Klinische Erfahrungen bei der Anwendung von Turisteron zur Behandlung des Prostatakarzinoms [Clinical experience using Turisteron in the treatment of prostatic cancer]. Z Urol Nephrol. 1987 Mar;80(3):181-3. German. PMID: 3604475. 12: Vachalovský V, Vomácka V. Turisteron v lécbĕ pokrocilého karcinomu prostaty [Turisteron in the treatment of advanced carcinoma of the prostate]. Rozhl Chir. 1985 Nov;64(11):718-22. Czech. PMID: 4089702. 13: Zade W, Schott H. Leberschäden unter der Hormontherapie des Prostatakarzinoms [Liver damage in hormone therapy of prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):177-9. German. PMID: 3604474. 14: Langkopf B. Zur Therapie des fortgeschrittenen Prostatakarzinoms [Therapy of advanced prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):121-4. German. PMID: 3111121.